{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:06:12Z","timestamp":1789545972486,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004095","name":"Kyowa Kirin Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone Reports"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bonr.2026.101944","type":"journal-article","created":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T14:33:00Z","timestamp":1788100380000},"page":"101944","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Burosumab improves alkaline phosphatase and rickets severity in X-linked hypophosphatemia: 3-year SUNFLOWER analysis"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6517-8825","authenticated-orcid":false,"given":"Keiichi","family":"Ozono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Gyung","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Namba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuo","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Shintani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Kanematsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimi","family":"Michigami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bonr.2026.101944_bb0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/082585979601200102","article-title":"Palliative performance scale (PPS): a new tool","volume":"12","author":"Anderson","year":"1996","journal-title":"J. Palliat. Care"},{"key":"10.1016\/j.bonr.2026.101944_bb0010","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.688309","article-title":"X-linked hypophosphatemic rickets: multisystemic disorder in children requiring multidisciplinary management","volume":"12","author":"Baroncelli","year":"2021","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.bonr.2026.101944_bb0015","author":"Bellamy"},{"issue":"12","key":"10.1016\/j.bonr.2026.101944_bb0020","first-page":"1833","article-title":"Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee","volume":"15","author":"Bellamy","year":"1988","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bonr.2026.101944_bb0025","doi-asserted-by":"crossref","DOI":"10.1177\/20406223241247643","article-title":"Real-world non-interventional post-authorization safety study of long-term use of burosumab in children and adolescents with X-linked hypophosphatemia: first interim analysis","volume":"15","author":"Boot","year":"2024","journal-title":"Ther. Adv. Chronic Dis."},{"issue":"7","key":"10.1016\/j.bonr.2026.101944_bb0030","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/jbmr.340","article-title":"A clinician\u2019s guide to X-linked hypophosphatemia","volume":"26","author":"Carpenter","year":"2011","journal-title":"J. Bone Miner. Res."},{"issue":"21","key":"10.1016\/j.bonr.2026.101944_bb0035","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with X-linked hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.bonr.2026.101944_bb0040","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/EJE-15-0661","article-title":"Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms","volume":"174","author":"Che","year":"2016","journal-title":"Eur. J. Endocrinol."},{"issue":"5","key":"10.1016\/j.bonr.2026.101944_bb0045","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1373\/clinchem.2011.177741","article-title":"Closing the gaps in pediatric laboratory reference intervals: a CALIPER database of 40 biochemical markers in a healthy and multiethnic population of children","volume":"58","author":"Colantonio","year":"2012","journal-title":"Clin. Chem."},{"issue":"2","key":"10.1016\/j.bonr.2026.101944_bb0055","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0304-3959(83)90143-4","article-title":"Development of the Wisconsin brief pain questionnaire to assess pain in cancer and other diseases","volume":"17","author":"Daut","year":"1983","journal-title":"Pain"},{"key":"10.1016\/j.bonr.2026.101944_bb0060","doi-asserted-by":"crossref","first-page":"e230242","DOI":"10.20945\/2359-4292-2023-0242","article-title":"Efficacy and safety of burosumab compared with conventional therapy in patients with X-linked hypophosphatemia: a systematic review","volume":"68","author":"Dodamani","year":"2024","journal-title":"Arch. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.bonr.2026.101944_bb0065","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.bone.2008.02.014","article-title":"Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement","volume":"42","author":"Endo","year":"2008","journal-title":"Bone"},{"issue":"10","key":"10.1016\/j.bonr.2026.101944_bb0080","doi-asserted-by":"crossref","first-page":"e998","DOI":"10.1210\/clinem\/dgad223","article-title":"Effects of burosumab treatment on mineral metabolism in children and adolescents with X-linked hypophosphatemia","volume":"108","author":"Ewert","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.bonr.2026.101944_bb0085","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1007\/s12325-019-01193-0","article-title":"Exploring the burden of X-linked hypophosphataemia: an opportunistic qualitative study of patient statements generated during a technology appraisal","volume":"37","author":"Ferizovi\u0107","year":"2020","journal-title":"Adv. Ther."},{"issue":"8","key":"10.1016\/j.bonr.2026.101944_bb0090","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/jbmr\/zjaf063","article-title":"Real-world effectiveness of burosumab vs oral phosphate and active vitamin D in adults with X-linked hypophosphatemia","volume":"40","author":"Florenzano","year":"2025","journal-title":"J. Bone Miner. Res."},{"issue":"7","key":"10.1016\/j.bonr.2026.101944_bb0095","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"15","author":"Haffner","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"issue":"6","key":"10.1016\/j.bonr.2026.101944_bb0100","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1515\/jpem-2020-0734","article-title":"Switching from conventional therapy to burosumab injection has the potential to prevent nephrocalcinosis in patients with X-linked hypophosphatemic rickets","volume":"34","author":"Harada","year":"2021","journal-title":"J. Pediatr. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.bonr.2026.101944_bb0105","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0304-3959(01)00314-1","article-title":"The faces pain scale-revised: toward a common metric in pediatric pain measurement","volume":"93","author":"Hicks","year":"2001","journal-title":"Pain"},{"issue":"3","key":"10.1016\/j.bonr.2026.101944_bb0110","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11914-021-00669-9","article-title":"Burosumab for pediatric X-linked hypophosphatemia","volume":"19","author":"Imel","year":"2021","journal-title":"Curr. Osteoporos. Rep."},{"issue":"10189","key":"10.1016\/j.bonr.2026.101944_bb0115","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.bonr.2026.101944_bb0120","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1002\/jbmr.3843","article-title":"Burosumab improved histomorphometric measures of osteomalacia in adults with X-linked hypophosphatemia: a phase 3, single-arm, international trial","volume":"34","author":"Insogna","year":"2019","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bonr.2026.101944_bb0125","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1507\/endocrj.EJ21-0386","article-title":"Burden of disease of X-linked hypophosphatemia in Japanese and Korean patients: a cross-sectional survey","volume":"69","author":"Ito","year":"2022","journal-title":"Endocr. J."},{"issue":"6","key":"10.1016\/j.bonr.2026.101944_bb0130","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-036367","article-title":"Long-term outcomes for Asian patients with X-linked hypophosphataemia: rationale and design of the SUNFLOWER longitudinal, observational cohort study","volume":"10","author":"Kubota","year":"2020","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.bonr.2026.101944_bb0135","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jbspin.2019.01.012","article-title":"X-linked hypophosphatemia: management and treatment prospects","volume":"86","author":"Lambert","year":"2019","journal-title":"Joint Bone Spine"},{"issue":"1","key":"10.1016\/j.bonr.2026.101944_bb0140","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/jcph.1950","article-title":"Population pharmacokinetics and pharmacodynamics of burosumab in adult and pediatric patients with X-linked hypophosphatemia","volume":"62","author":"Lee","year":"2022","journal-title":"J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.bonr.2026.101944_bb0145","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1530\/EC-13-0103","article-title":"Therapeutic management of hypophosphatemic rickets from infancy to adulthood","volume":"3","author":"Linglart","year":"2014","journal-title":"Endocr. Connect."},{"issue":"3","key":"10.1016\/j.bonr.2026.101944_bb0150","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1210\/clinem\/dgab729","article-title":"Sustained efficacy and safety of burosumab, a monoclonal antibody to FGF23, in children with X-linked hypophosphatemia","volume":"107","author":"Linglart","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9","key":"10.1016\/j.bonr.2026.101944_bb0155","article-title":"Burosumab in Chinese adults with X-linked hypophosphatemia: a phase 4 study","volume":"9","author":"Liu","year":"2025","journal-title":"JBMR Plus."},{"issue":"8","key":"10.1016\/j.bonr.2026.101944_bb0160","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1210\/jc.2003-030036","article-title":"Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets","volume":"88","author":"M\u00e4kitie","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.bonr.2026.101944_bb0165","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvac021","article-title":"Safety and efficacy of burosumab in pediatric patients with X-linked hypophosphatemia: a phase 3\/4 open-label trial","volume":"6","author":"Namba","year":"2022","journal-title":"J. Endocr. Soc."},{"issue":"11","key":"10.1016\/j.bonr.2026.101944_bb0170","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1007\/s00467-022-05484-7","article-title":"Real-world effectiveness of burosumab in children with X-linked hypophosphatemic rickets","volume":"37","author":"Paloian","year":"2022","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.bonr.2026.101944_bb0175","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2024.1430921","article-title":"X-linked hypophosphatemic rickets and nephrocalcinosis: clinical characteristics of a single-center pediatric cohort in North America before and after burosumab","volume":"12","author":"Paloian","year":"2024","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.bonr.2026.101944_bb0180","series-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2018"},{"issue":"4","key":"10.1016\/j.bonr.2026.101944_bb0185","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1442-200X.2008.02700.x","article-title":"Nutritional rickets and z scores for height in the United Arab Emirates: to D or not to D?","volume":"50","author":"Rajah","year":"2008","journal-title":"Pediatr. Int."},{"key":"10.1016\/j.bonr.2026.101944_bb0190","series-title":"Development, validation, and norming of the SF-10 for Children Health Survey [Abstract]","first-page":"A","volume":"15","author":"Saris-Baglama","year":"2006"},{"issue":"1","key":"10.1016\/j.bonr.2026.101944_bb0195","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00198-020-05548-0","article-title":"Burden of disease associated with X-linked hypophosphataemia in adults: a systematic literature review","volume":"32","author":"Seefried","year":"2021","journal-title":"Osteoporos. Int."},{"issue":"7","key":"10.1016\/j.bonr.2026.101944_bb0200","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1210\/js.2018-00365","article-title":"The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey","volume":"3","author":"Skrinar","year":"2019","journal-title":"J. Endocr. Soc."},{"issue":"3","key":"10.1016\/j.bonr.2026.101944_bb0205","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/tropej\/46.3.132","article-title":"Radiographic scoring method for the assessment of the severity of nutritional rickets","volume":"46","author":"Thacher","year":"2000","journal-title":"J. Trop. Pediatr."},{"key":"10.1016\/j.bonr.2026.101944_bb0210","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bone.2019.02.010","article-title":"Rickets severity predicts clinical outcomes in children with X-linked hypophosphatemia: utility of the radiographic rickets severity score","volume":"122","author":"Thacher","year":"2019","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.bonr.2026.101944_bb0215","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1136\/archdischild-2022-324962","article-title":"Burosumab in management of X-linked hypophosphataemia: a retrospective cohort study of growth and serum phosphate levels","volume":"108","author":"Walker","year":"2023","journal-title":"Arch. Dis. Child."},{"issue":"9","key":"10.1016\/j.bonr.2026.101944_bb0225","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1210\/clinem\/dgag140","article-title":"Real-world effectiveness of burosumab across age groups: X-linked hypophosphatemia (XLH) disease monitoring program","volume":"111","author":"Ward","year":"2026","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.bonr.2026.101944_bb0220","doi-asserted-by":"crossref","DOI":"10.1093\/jbmrpl\/ziad001","article-title":"Burosumab vs conventional therapy in children with X-linked hypophosphatemia: results of the open-label, phase 3 extension period","volume":"8","author":"Ward","year":"2024","journal-title":"JBMR Plus."},{"issue":"1","key":"10.1016\/j.bonr.2026.101944_bb0230","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1210\/clinem\/dgac518","article-title":"Long-term burosumab administration is safe and effective in adults with X-linked hypophosphatemia","volume":"108","author":"Weber","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.bonr.2026.101944_bb0235","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/jbmr.3377","article-title":"Validation of a novel scoring system for changes in skeletal manifestations of hypophosphatasia in newborns, infants, and children: the radiographic global impression of change scale","volume":"33","author":"Whyte","year":"2018","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.bonr.2026.101944_bb0240","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S2213-8587(18)30338-3","article-title":"Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial","volume":"7","author":"Whyte","year":"2019","journal-title":"Lancet Diabetes Endocrinol."}],"container-title":["Bone Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352187226000483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352187226000483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:39:29Z","timestamp":1789544369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352187226000483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":45,"alternative-id":["S2352187226000483"],"URL":"https:\/\/doi.org\/10.1016\/j.bonr.2026.101944","relation":{},"ISSN":["2352-1872"],"issn-type":[{"value":"2352-1872","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Burosumab improves alkaline phosphatase and rickets severity in X-linked hypophosphatemia: 3-year SUNFLOWER analysis","name":"articletitle","label":"Article Title"},{"value":"Bone Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bonr.2026.101944","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101944"}}